Codexis, Inc. (NASDAQ:CDXS)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday. They presently have a $8.50 target price on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 45.30% from the company’s current price.

Other equities analysts have also issued research reports about the company. Zacks Investment Research lowered Codexis from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. BidaskClub downgraded Codexis from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Jefferies Group LLC boosted their price objective on Codexis from $9.00 to $11.00 and gave the company a “buy” rating in a report on Friday, October 13th. Finally, ValuEngine upgraded Codexis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $7.50.

Shares of Codexis (NASDAQ CDXS) remained flat at $$5.85 during trading on Tuesday. 194,800 shares of the company’s stock traded hands, compared to its average volume of 169,046. Codexis has a twelve month low of $3.60 and a twelve month high of $7.95.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/21/codexis-inc-cdxs-rating-reiterated-by-hc-wainwright.html.

In other news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of the stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $5.78, for a total value of $6,126,800.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 9.80% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Menta Capital LLC boosted its position in shares of Codexis by 1.5% in the 1st quarter. Menta Capital LLC now owns 41,378 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 600 shares during the period. Bank of America Corp DE boosted its position in shares of Codexis by 2.9% in the 1st quarter. Bank of America Corp DE now owns 25,477 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 717 shares during the period. TIAA CREF Investment Management LLC boosted its position in shares of Codexis by 1.1% in the 1st quarter. TIAA CREF Investment Management LLC now owns 102,294 shares of the biotechnology company’s stock valued at $491,000 after purchasing an additional 1,099 shares during the period. EAM Investors LLC boosted its position in shares of Codexis by 0.4% in the 4th quarter. EAM Investors LLC now owns 407,255 shares of the biotechnology company’s stock valued at $1,723,000 after purchasing an additional 1,604 shares during the period. Finally, Nationwide Fund Advisors boosted its position in shares of Codexis by 15.7% in the 2nd quarter. Nationwide Fund Advisors now owns 21,568 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 2,928 shares during the period. Institutional investors and hedge funds own 63.65% of the company’s stock.

Codexis Company Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.